@article{
author = "Vuković-Dejanović, Vesna and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Bogavac-Stanojević, Nataša",
year = "2022",
abstract = "Statins have been shown to decrease inflammatory markers, especially high sensitivity C reactive protein (hsCRP), in a dose-dependent manner. Pentraxin-3 (PTX3) is another important inflammatory biomarker from the pentraxin family that provides useful prognostic information and facilitates diagnostics of cardiovascular diseases. This study investigated the effect of statin therapy on PTX3 and hsCRP concentrations and whether statins acted synergistically with PTX3 and hsCRP concentrations in lowering LDL-C. The study group consisted of 90 patients undergoing coronary angiography. The results showed that statins reduced PTX3 concentrations (p=0.031). PTX3 and hsCRP levels were significantly different between subclinical and severe stenosis groups (p=0.011 and p=0.009, respectively). Statin therapy was significantly associated with lower PTX3 and LDL-C levels in multiple logistic analyses. The probability that statin therapy would achieve target LDL-C values was highest in patients with low PTX3 values (OR=3.683, p=0.040), while multiplicative interaction was 23.3. The effect of statins on PTX3 reduction was higher than on hsCRP. It can be suggested that statin therapy was more successful in patients with low PTX3 values., Pokazano je da statini snižavaju koncentracije inflamatornih markera, posebno visoko osetljivog C reaktivnog proteina (hsCRP), pri čemu je sniženje zavisno od doze leka. Pentraksin- 3 (PTX3) je još jedan važan inflamatorni biomarker iz porodice pentraksina koji ima prognostičke karakteristike i olakšava dijagnozu kardiovaskularnih bolesti. U ovoj studiji je ispitivan efekat terapije statinima na koncentracije PTX3 i hsCRP, kao i sinergistički efekat terapije, koncentracija PTX3 i hsCRP u snižavanju LDL-C. U studiju je uključeno 90 pacijenata kojima je koronarnom angiografijom procenjeno suženje koronarnih krvnih sudova. Rezultati su pokazali da statini smanjuju koncentraciju PTX3 (p=0,031). Koncentracije PTX3 i hsCRP značajno se razlikuju između grupa sa subkliničkim (p=0,011) i teškim oblikom stenoze (p=0,009). Primenom multiple logističke regresione analize uočena je veza između terapije statinima i niskih koncentracija PTX3 i LDL-C. Verovatnoća da će terapija statinima postići ciljne vrednosti LDL- C bila je najveća kod pacijenata sa niskim vrednostima PTX3 (OR=3,683, p=0,040), dok je multiplikativna interakcija bila 23,3. Efekat statina na sniženje PTX3 bio je veći u odnosu na efekat koji ostvaruje na hsCRP. Može se sugerisati da je terapija statinima bila uspešnija kod pacijenata sa niskim vrednostima PTX3.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Does Pentraxin-3 contribute to the reduction of low-density lipoprotein levels by statin therapy?, Da li pentraksin -3 doprinosi sniženju koncentracije lipoproteina niske gustine i terapiji statinima?",
volume = "72",
number = "2",
pages = "247-259",
doi = "10.5937/arhfarm72-36122"
}
